The Peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone Ameliorates Murine Lupus by Induction of Adiponectin
- 1 January 2009
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 182 (1), 340-346
- https://doi.org/10.4049/jimmunol.182.1.340
Abstract
Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease for which current therapy is suboptimal. SLE is characterized by autoantibody production, with renal disease and premature atherosclerosis being common and severe manifestations causing appreciable morbidity and mortality. Peroxisome proliferator-activated receptor γ (PPARγ) agonists are widely used in the treatment of diabetes mellitus for their insulin-sensitizing properties, but also have immunomodulatory effects. In this report, we show that the PPARγ agonist rosiglitazone reduces autoantibody production, renal disease, and atherosclerosis in mouse models of SLE. The beneficial effect of rosiglitazone on SLE manifestations depends on the induction of adiponectin, because rosiglitazone has no effect on autoantibody production or renal disease in lupus mice that lack adiponectin. In addition, lupus mice that lack adiponectin develop more severe disease than adiponectin-sufficient lupus mice, indicating that endogenous adiponectin is involved in regulating disease activity. Furthermore, administration of exogenous adiponectin ameliorates disease. These experiments suggest that PPARγ agonists may be useful agents for the treatment of SLE. They also demonstrate that induction of adiponectin is a major mechanism underlying the immunomodulatory effects of PPARγ agonists.Keywords
This publication has 63 references indexed in Scilit:
- Prevalence and Factors Associated With Metabolic Syndrome in Patients With Rheumatoid Arthritis and Systemic Lupus ErythematosusJCR: Journal of Clinical Rheumatology, 2008
- Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled TrialGastroenterology, 2008
- Role of resistin as a marker of inflammation in systemic lupus erythematosusArthritis Research & Therapy, 2008
- Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ AgonistsThe American Journal of Cardiology, 2007
- Adiponectin modulates inflammatory reactions via calreticulin receptor–dependent clearance of early apoptotic bodiesJCI Insight, 2007
- Adipocytokines: mediators linking adipose tissue, inflammation and immunityNature Reviews Immunology, 2006
- Adiponectin inhibits Toll‐like receptor family‐induced signalingFEBS Letters, 2005
- Cloning of adiponectin receptors that mediate antidiabetic metabolic effectsNature, 2003
- Inflammatory Markers, Adiponectin, and Risk of Type 2 Diabetes in the Pima IndianDiabetes Care, 2003
- mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.Genes & Development, 1994